Innovent Biologics, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (5)

Latest Posts

About This Stock More About This Stock
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
Article By: ChinaBio® Today
Saturday, May 25, 2024 4:00 PM EDT
Jiangsu Hengrui Medicine out-licensed global rights for its portfolio of three proprietary GLP-1 candidates to a US startup, Hercules, in a deal worth up to $6 billion. Hengrui will receive $110 million upfront and up to $200 million in milestones.
In this article: AZN, BGNE, TAK, IVBXF, CSPHF
Read
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Article By: ChinaBio® Today
Saturday, April 6, 2024 1:20 PM EDT
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates for solid tumors.
In this article: INCY, GMAB, CHSYF, BMY, HCM, ZLAB, IVBXF Also: ASND
Read
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Article By: ChinaBio® Today
Saturday, March 23, 2024 2:00 PM EDT
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.
In this article: MRK, NVO, BGNE, WXXWY, IVBXF, WUXIF Also: NVS, CTLT
Read
Week In Review: EurekaBio Raises $40 Million To Support Lentiviral Vector Platform
Article By: ChinaBio® Today
Saturday, March 9, 2024 2:20 PM EDT
Shenzhen EurekaBio closed a $40 Series B+ funding to support the commercialization of its EuLV Lentiviral Vector Production System, a technology that the company believes could transform large-scale production of lentiviral vectors.
In this article: AVGR, IVBXF, AKESF
Read
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
Article By: ChinaBio® Today
Saturday, March 2, 2024 2:00 PM EDT
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global rights for Roxadustat to FibroGen.
In this article: AZN, TEVA, FGEN, KZR, IVBXF, IRON
Read

Latest Tweets for $IVBXF

No tweets yet!

PARTNER HEADLINES